Alumis Inc. unveils late-stage immunology pipeline and key upcoming clinical milestones
Alumis Inc. has unveiled its late-stage precision immunology pipeline, featuring three clinical-stage molecules: Envudeucitinib for psoriasis and SLE, A-005 for multiple sclerosis, and Lonigutamab for thyroid eye disease. Key milestones include Phase 3 data for Envudeucitinib in early Q1 2026 and Phase 2b data in SLE by Q3 2026. The company had $377.7 million in cash as of September 30, 2025, to fund operations into 2027.
Alumis Inc. has released a corporate presentation highlighting progress in its late-stage precision immunology pipeline. The company’s portfolio includes three clinical-stage molecules: Envudeucitinib, a TYK2 inhibitor for psoriasis and systemic lupus erythematosus (SLE); A-005, a CNS-penetrant TYK2 inhibitor for multiple sclerosis and other neuroinflammatory diseases; and Lonigutamab, an anti-IGF-1R therapy for thyroid eye disease. Top-line Phase 3 data for Envudeucitinib in psoriasis are expected in early Q1 2026, with Phase 2b data in SLE anticipated in Q3 2026. The presentation notes that the company had $377.7 million in cash, cash equivalents, and marketable securities as of September 30, 2025, projected to fund operations into 2027. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
